QR код

Combinational BET and mTOR inhibition unveils EGR1 as acute myeloid leukemia prognostic biomarker

Abstract This study investigated the anti-leukemic potential of BET inhibitors in combination with mTOR inhibitors, focusing on both BET-resistant and BET-sensitive AML cell lines. Our findings reveal a significant suppression of proliferation and induction of apoptosis across all tested cell lines...

Повний опис

Збережено в:
Автори: Marcela Teatin Latancia, Wellington Fernandes da Silva, Elayne Bragança-Jardim, Fernanda Fernandes Terra, Paula Fontes Asprino, Welbert De Oliveira Pereira, Vanessa Candiotti Buzatto, Pedro Alexandre Galante, Lilian Tiemi Inoue, Ana Rita Fonseca, Thais Nascimento Kimmemgs, Celso Arrais-Rodrigues, Vanderson Rocha, Yana Novis, Niels Olsen Saraiva Camara, Ana Paula Lepique, Luiz Fernando Lima Reis, Mariane Tami Amano
Формат: Artigo
Мова:Inglês
Опубліковано: Nature Portfolio 2025-11-01
Серія:Scientific Reports
Предмети:
Leukemia
mTOR
Bromodomain
Epigenetics
Cancer treatment
Inhibitors
Онлайн доступ:https://doi.org/10.1038/s41598-025-24366-0
Теги: Додати тег
Немає тегів, Будьте першим, хто поставить тег для цього запису!

Схожі ресурси